Biosimilar Growth Hormones Market Report 2026

The biosimilar growth hormones market size has grown rapidly in recent years. It will grow from $0.89 billion in 2025 to $0.98 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to high cost of branded growth hormone therapies, increasing prevalence of growth hormone deficiency, rising pediatric growth disorder diagnoses, limited access to affordable treatment options, dependence on hospital-based administration.

The biosimilar growth hormones market size is expected to see rapid growth in the next few years. It will grow to $1.46 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to patent expiry of branded growth hormones, increasing approval of biosimilars, expansion of self-administration therapies, rising awareness of growth disorders, growing healthcare expenditure in emerging markets. Major trends in the forecast period include increasing adoption of cost-effective biosimilar growth hormones, rising demand for pediatric and adult growth hormone therapies, growing preference for self-administration via subcutaneous route, expansion of online pharmacies and specialty clinics, improving regulatory acceptance of biosimilars.

The increasing number of children affected by growth hormone deficiency is contributing to the growth of the global biosimilar growth hormone market. Growth hormone deficiency occurs due to damage to the pituitary gland or hypothalamus and may result from abnormal development before birth (congenital) or from conditions or events occurring during or after birth (acquired). For example, in September 2023, according to Hormones Australia by the Endocrine Society of Australia (ESA), an Australia-based national authority for endocrine-related conditions and diseases, growth hormone deficiency is estimated to affect 2 to 3 individuals per 10,000 people. As a result, the rising number of children experiencing growth deficiencies is driving the expansion of the biosimilar growth hormone market.

Major companies operating in the biosimilar growth hormone market are focusing on developing innovative solutions, such as human growth hormone therapies, to improve treatment effectiveness and affordability for patients with growth hormone deficiencies. Growth hormone solutions are medical treatments designed to supplement or replace human growth hormone in individuals with inadequate hormone production. For instance, in June 2023, Pfizer Inc., a US-based pharmaceutical company, in collaboration with OPKO Health Inc., a US-based healthcare company, received approval from the US Food and Drug Administration for NGENLA (somatrogon-ghla). This once-weekly injectable human growth hormone therapy is intended for pediatric patients with growth hormone deficiency and offers an alternative to daily injections, improving treatment convenience and adherence for patients and caregivers. The approval was supported by clinical trial data demonstrating its safety and efficacy, representing a significant advancement in growth hormone treatment options.

In October 2023, Amgen, a US-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition aligns with Amgen’s strategy to deliver innovative treatments for patients with serious illnesses and includes Horizon’s products such as Tepezza for thyroid eye disease, Krystexxa for chronic refractory gout, and Uplizna for neuromyelitis optica spectrum disorder. The transaction is expected to accelerate revenue growth and strengthen cash flow, supporting continued innovation. Horizon Therapeutics plc is an Ireland-based biotechnology company.

Major companies operating in the biosimilar growth hormones market are Amega Biotech, Biosidus S.A., Eli Lilly and Company, Ferring Pharmaceuticals, Genetech Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Sanofi S.A., USV Private Limited, Zhongshan Hygene Biopharm Co. Ltd., Biopartners And LG Chem, Boehringer Ingelheim International GmbH, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc., Genor Biopharma Co. Ltd., Hetero Drugs Limited, Intas Pharmaceuticals Ltd., LG Chem Ltd., Lupin Limited, Mabion S.A., Mundipharma International Limited, Panacea Biotec Limited, Pfenex Inc., PlantForm Corporation.

North America was the largest region in the biosimilar growth hormone market in 2025. The Middle East is expected to be the fastest-growing region in the biosimilar growth hormones market report during the forecast period. The regions covered in the biosimilar growth hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biosimilar growth hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the biosimilar growth hormones market by increasing the cost of imported active pharmaceutical ingredients, biologics manufacturing equipment, and cold-chain logistics. Subcutaneous and intravenous formulations distributed through hospital and retail pharmacies are most affected, particularly in regions such as North America and Europe that rely on cross-border supply chains. These tariffs have raised production and distribution costs, impacting pricing and accessibility. However, they have also encouraged local manufacturing, regional supply chain development, and investments in domestic biosimilar production capabilities.

The biosimilar growth hormones market research report is one of a series of new reports that provides biosimilar growth hormones market statistics, including biosimilar growth hormones industry global market size, regional shares, competitors with a biosimilar growth hormones market share, detailed biosimilar growth hormones market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar growth hormones industry. This biosimilar growth hormones market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biosimilar growth hormone refers to a peptide hormone that stimulates cell growth, cell division, and cellular regeneration in humans and other animals, making it essential for normal growth and development. It functions as a mitogen that acts on specific types of cells.

The primary routes of administration for biosimilar growth hormones include intravenous, subcutaneous, intramuscular, and oral. Intravenous administration is a medical method in which fluids, medications, or nutrients are delivered directly into a patient’s vein. These therapies are used for various applications such as growth hormone deficiency, Turner syndrome, idiopathic short stature, Prader-Willi syndrome, and others, and are distributed through multiple channels including hospital and retail pharmacies, online pharmacies or e-pharmacies, and specialty clinics.

The biosimilar growth hormone market consists of sales of teriparatide, follitropin alfa, insulin, and somatropin. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.